Johan Lanng Nielsen

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Stephen G. O’Brien, François Guilhot, Richard A. Larson et al. · New England Journal of Medicine · 2003 · 3.5K citations · Full text

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.

Stig Lenhoff, Martin Hjorth, Erik Holmberg et al. · PubMed · 2000 · 312 citations

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

Anders Waage, Peter Gimsing, Peter Fayers et al. · Blood · 2010 · 231 citations · Full text

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

Michele Baccarani, Gianantonio Rosti, Fausto Castagnetti et al. · Blood · 2009 · 196 citations